(S)-(+)-2-Amino-1-piperidinopropan | 82504-99-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-(+)-2-Amino-1-piperidinopropan
• 英文别名: (S)-1-(2-Amino-propan-1-yl)-piperidine；(2S)-1-piperidin-1-ylpropan-2-amine
• CAS: 82504-99-2
• 化学式: C₈H₁₈N₂
• mdl: MFCD01318922
• 分子量: 142.244
• InChiKey: ZFDABCDCTKLGOK-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-(+)-2-Amino-1-piperidinopropan 在 铜 作用下， 反应 29.0h， 生成 N-((S)-1-Methyl-2-piperidin-1-yl-ethyl)-N-pyridin-2-yl-acetamide
  参考文献：
  名称：

  Woliweber, European Journal of Medicinal Chemistry, 1982, vol. 17, # 2, p. 125 - 133

  摘要：

  DOI：
• 作为产物：
  描述：

  1-甲基-2-哌啶-1-乙胺 生成 (S)-(+)-2-Amino-1-piperidinopropan
  参考文献：
  名称：

  Woliweber, European Journal of Medicinal Chemistry, 1982, vol. 17, # 2, p. 125 - 133

  摘要：

  DOI：

文献信息

• Synthesis and antimalarial activity of new 4-aminoquinolines active against drug resistant strains
  作者：Srinivasarao Kondaparla、Awakash Soni、Ashan Manhas、Kumkum Srivastava、Sunil K. Puri、S. B. Katti

  DOI：10.1039/c6ra14016e

  日期：——

  containing basic tertiary terminal nitrogen and bioevaluated them for antimalarial activity against Plasmodium falciparum in vitro (CQ-sensitive strain-3D7 & CQ-resistant strain-K1) and Plasmodium yoelii in vivo (N-67 strain). Among the series, thirteen compounds showed superior antimalarial activity against K1 strain as compared to CQ. In addition, all these analogs showed 100% suppression of parasitaemia

  在本研究中，我们通过用含有碱性叔末端氮的无环和/或环胺基团取代氯喹（CQ）的二乙胺官能团，合成了一类新的4-氨基喹啉衍生物，并对它们在体外对恶性疟原虫的抗疟活性进行了生物评价。（CQ敏感菌株3D7和CQ耐药菌株K1）和约氏疟原虫体内（N-67菌株）。在该系列中，与CQ相比，十三种化合物对K1菌株表现出优异的抗疟活性。此外，所有这些类似物在体内在第4天都显示出100％的寄生虫血症抑制口服时可抵抗N-67毒株的小鼠模型。此外，生物物理研究表明这些化合物对血红素聚合目标起作用。
• INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
  申请人：Janssen Pharmaceutica NV

  公开号：US20200055874A1

  公开（公告）日：2020-02-20

  Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

  Sultam化合物，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与KEAP1-Nrf2相互作用相关的疾病状态、疾病和病况的方法，如炎症性肠病，包括克罗恩病和溃疡性结肠炎。
• ANTIPROTOZOAL COMPOUNDS
  申请人：Bacoba AG

  公开号：EP3345917A1

  公开（公告）日：2018-07-11

  The present invention relates to a compound of formula (I) wherein --A-- represents a peptide chain, wherein said peptide chain consists of 5 to 7 amino acids, wherein said amino acids are selected from any amino acid, wherein at least two, preferably at least three of said 5 to 7 amino acids are α-aminoisobutyric acid (Aib), leucine (Leu) or alanine (Ala); R1 is wherein X is N or CH; R5 is selected from H, C1-C16alkyl, C1-C16alkenyl, C(O)-C1-C16alkyl, C(O)-C1-C16alkenyl, (wherein said C1-C16alkyl, C1-C16alkenyl, C(O)-C1-C16alkyl, C(O)-C1-C16alkenyl are) independently optionally substituted with halogen, NR11R12, -[O-C2H4]n-OCH3 wherein n=2-20; C(O)-R8, C(O)-C1-C3alkylene-R8, N(H)C(O)-R8, or S(O)2-R9, wherein R8 is independently at each occurrence selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, each independently optionally substituted with C1-C4alkyl, halogen, CF3, OR10, NR11R12, C6H5 and C6H5 substituted with halogen, C1-C3alkyl, OR10, NR11R12; wherein R10, R11, R12 are independently at each occurrence H, C1-C3alkyl; R9 is independently at each occurrence selected from C1-C4alkyl, aryl, heteroaryl, each independently optionally substituted with C1-C4alkyl, halogen, CF3, OR13, NR14R15; wherein R13, R14, R15 are independently at each occurrence H, C1-C3alkyl; R6, R7 are independently at each occurrence selected from H, C1-C4alkyl, C1-C4alkenyl, C(O)-C1-C3alkyl, C(O)-C1-C4alkenyl, (wherein said C1-C4alkyl, C1-C4alkenyl, C(O)-C1-C3alkyl, C(O)-C1-C4alkenyl are) independently optionally substituted with halogen, NR11R12; or R6 and R7 together with the X-C to which they are attached form independently at each occurrence an aryl, heteroaryl, cycloalkyl, heterocyclyl, each independently optionally (further) substituted with C1-C4alkyl, halogen, CF3, OR10, NR11R12, C6H5 and C6H5 substituted with halogen, C1-C3alkyl, OR10, NR11R12; wherein R10, R11, R12 are independently at each occurrence H, C1-C3alkyl; and wherein the arrow indicates the attachment to the NH-moiety depicted in formula (I); R2 is selected from C1-C14alkyl, C2-C14alkyl optionally substituted with OH, C2-C14alkoxy, C2-C14alkenyl optionally substituted with OH; C1-C8alkylene-R23, wherein in alkylene one or two -CH2- moieties are optionally replaced by -CH(NR24R25)-,-CH(OH)-, -C(=O)-, -NR24R25- or -CH(CH3)- moieties, wherein there are no adjacent-C(=O)- moieties or adjacent -NR24R25- moieties, and wherein R23 is independently at each occurrence selected from hydrogen; aryl, heteroaryl, cycloalkyl, heterocyclyl, each independently optionally substituted with C1-C4alkyl, OR26, NR27R28; wherein R26, R27, R28 are independently at each occurrence H, halogen, CF3, C1-C3alkyl; and wherein R24 and R25 are independently at each occurrence H, C1-C3alkyl; with the proviso that R2 is not -CH2CH(CH3)CH2CH(OH)CH2C(O)C2H5, -CH2CH(CH3)CH2CH=CHC(O)C2H5, -CH2CH(CH3)CH2CH2CH2C(O)C2H5, -CH2CH(CH3)(CH2)3CH(OH)C2H5, -CH2CH(CH3)CH2CH(OCH3)CH2C(O)C2H5; R3 is selected from C2-C12alkyl optionally substituted with OH, C2-C12alkoxy, C2-C12alkenyl optionally substituted with OH, C1-C8alkylene-R29, wherein in alkylene one or two -CH2- moieties are optionally replaced by -CH(NR30R31)-, -CH(OH)-, -C(=O)-, -NR30R31- or -CH(CH3)- moieties, wherein there are no adjacent -C(=O)- moieties or adjacent -NR30R31- moieties, and wherein R29 is independently at each occurrence selected from hydrogen; aryl, heteroaryl, cycloalkyl, heterocyclyl, each independently optionally substituted with C1-C4alkyl, OR32, NR33R34; wherein R32, R33, R34 are independently at each occurrence H, halogen, CF3, C1-C3alkyl; and wherein R30 and R31 are independently at each occurrence H, C1-C3alkyl; R4 is wherein R35 is independently selected from hydrogen and C1-C3-alkyl; R36 is independently at each occurrence selected from -cycloalkyl-NR41R42, wherein said cycloalkyl moiety is optionally substituted by C1-C4alkyl, hydroxyl, halogen, OR43; -C3-C6alkylene-NR41R42, wherein said C3-C6alkylene moiety is optionally substituted by hydroxyl, OR43, halogen; cycloalkyl optionally substituted with C1-C4alkyl, halogen, OR43; or wherein R35 and R36 together with the nitrogen atom to which they are attached form independently at each occurrence a heteroaryl, a heterocyclyl or a heterocyclic spiranyl, each independently optionally substituted with C1-C4alkyl, halogen, OR43, NR44R45, wherein R43, R44, R45 are independently at each occurrence H, C1-C4alkyl; and wherein R37, R38, R39 and R40 are independently at each occurrence H or C1-C3alkyl, preferably H or methyl, or independently at each occurrence two of said R37, R38, R39 and R40 together with the carbon atom to which they are attached form a carbocyclic or heterocyclic ring, preferably a carbocyclic ring, and wherein R41 and R42 are independently of each other H or C1-C4alkyl optionally substituted with halogen, hydroxyl or C3-C6cycloalkyl; or together with the nitrogen atoms to which they are attached form independently at each occurrence a heteroaryl or a heterocyclyl, each independently optionally substituted with halogen, C1-C4alkyl, OR43, NR44R45; wherein the arrow indicates the attachment to the C(O)-moiety depicted in formula (I); and pharmaceutically acceptable salts of said compound of formula (I). The present invention further relates to pharmaceutical compositions comprising said compounds and to the use of said compounds in a method of treatment of a protozoan disease, wherein preferably said protozoan disease is selected from malaria, human African trypanosomiasis, Chagas disease or leishmaniasis.

  本发明涉及式(I)的化合物，其中--A--表示一条肽链，所述肽链由5至7个氨基酸组成，其中所述氨基酸选自任何氨基酸，其中所述5至7个氨基酸中至少有两个、优选至少三个为α-氨基异丁酸(Aib)、亮氨酸(Leu)或丙氨酸(Ala)； R1是： 其中，X为N或CH； R5选自H、C1-C16烷基、C1-C16烯基、C(O)-C1-C16烷基、C(O)-C1-C16烯基(其中所述C1-C16烷基、C1-C16烯基、C(O)-C1-C16烷基、C(O)-C1-C16烯基)各自可独立地被卤素、NR11R12、-[O-C2H4]n-OCH3(其中n=2-20)取代；C(O)-R8、C(O)-C1-C3亚烷基-R8、N(H)C(O)-R8、或S(O)2-R9，其中： R8在每次出现时独立地选自芳基、杂芳基、环烷基、杂环基，各自独立地可被C1-C4烷基、卤素、CF3、OR10、NR11R12、C6H5和被卤素、C1-C3烷基、OR10、NR11R12取代的C6H5取代；其中R10、R11、R12在每次出现时独立地为H、C1-C3烷基； R9在每次出现时独立地选自C1-C4烷基、芳基、杂芳基，各自独立地可被C1-C4烷基、卤素、CF3、OR13、NR14R15取代；其中R13、R14、R15在每次出现时独立地为H、C1-C3烷基； R6、R7在每次出现时独立地选自H、C1-C4烷基、C1-C4烯基、C(O)-C1-C3烷基、C(O)-C1-C4烯基(其中所述C1-C4烷基、C1-C4烯基、C(O)-C1-C3烷基、C(O)-C1-C4烯基)各自独立地可被卤素、NR11R12取代；或R6和R7与所连接的X-C基团共同形成独立地在每次出现时为芳基、杂芳基、环烷基、杂环基，各自独立地可被C1-C4烷基、卤素、CF3、OR10、NR11R12、C6H5和被卤素、C1-C3烷基、OR10、NR11R12取代的C6H5取代；其中R10、R11、R12在每次出现时独立地为H、C1-C3烷基；其中箭头指示连接至式(I)中所示的NH基团； R2选自C1-C14烷基、C2-C14烷基可选地被OH、C2-C14烷氧基、C2-C14烯基可选地被OH取代；C1-C8亚烷基-R23，其中亚烷基中的一或两个-CH2-基团可选地被-CH(NR24R25)-、-CH(OH)-、-C(=O)-、-NR24R25-或-CH(CH3)-基团取代，且不存在相邻的-C(=O)-基团或相邻的-NR24R25-基团，且其中： R23在每次出现时独立地选自氢；芳基、杂芳基、环烷基、杂环基，各自独立地可被C1-C4烷基、OR26、NR27R28取代；其中R26、R27、R28在每次出现时独立地为H、卤素、CF3、C1-C3烷基；且其中R24和R25在每次出现时独立地为H、C1-C3烷基； 条件是R2不为-CH2CH(CH3)CH2CH(OH)CH2C(O)C2H5、-CH2CH(CH3)CH2CH=CHC(O)C2H5、-CH2CH(CH3)CH2CH2CH2C(O)C2H5、-CH2CH(CH3)(CH2)3CH(OH)C2H5、-CH2CH(CH3)CH2CH(OCH3)CH2C(O)C2H5； R3选自C2-C12烷基可选地被OH、C2-C12烷氧基、C2-C12烯基可选地被OH取代，或C1-C8亚烷基-R29，其中亚烷基中的一或两个-CH2-基团可选地被-CH(NR30R31)-、-CH(OH)-、-C(=O)-、-NR30R31-或-CH(CH3)-基团取代，且不存在相邻的-C(=O)-基团或相邻的-NR30R31-基团，且其中： R29在每次出现时独立地选自氢；芳基、杂芳基、环烷基、杂环基，各自独立地可被C1-C4烷基、OR32、NR33R34取代；其中R32、R33、R34在每次出现时独立地为H、卤素、CF3、C1-C3烷基；且其中R30和R31在每次出现时独立地为H、C1-C3烷基； R4为： 其中R35独立地选自氢和C1-C3烷基； R36在每次出现时独立地选自-环烷基-NR41R42的环烷基部分可选地被C1-C4烷基、羟基、卤素、OR43取代；-C3-C6亚烷基-NR41R42的C3-C6亚烷基部分可选地被羟基、OR43、卤素取代；环烷基可选地被C1-C4烷基、卤素、OR43取代；或R35和R36与所连接的氮原子共同形成独立地在每次出现时为杂芳基、杂环基或杂环螺旋基，各自独立地可被C1-C4烷基、卤素、OR43、NR44R45取代，其中R43、R44、R45在每次出现时独立地为H、C1-C4烷基；且其中： R37、R38、R39和R40在每次出现时独立地为H或C1-C3烷基，优选H或甲基，或在每次出现时R37、R38、R39和R40中的两个与所连接的碳原子共同形成碳环或杂环环，优选为碳环，且其中： R41和R42彼此独立地为H或C1-C4烷基(可选地被卤素、羟基或C3-C6环烷基取代)；或与所连接的氮原子共同形成独立地在每次出现时为杂芳基或杂环基，各自独立地可被卤素、C1-C4烷基、OR43、NR44R45取代；其中 箭头指示连接至式(I)中所示的C(O)基团；以及式(I)化合物的药学上可接受的盐。 本发明还涉及包含所述化合物的药物组合物，以及所述化合物在治疗原虫病的方法中的用途，其中优选所述原虫病选自疟疾、人类非洲锥虫病、查加斯病或利什曼病。
• Inhibitors of KEAP1-Nrf2 protein-protein interaction
  申请人：Janssen Pharmaceutica NV

  公开号：US10947252B2

  公开（公告）日：2021-03-16

  Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

  Sultam化合物、含有这些化合物的药物组合物、制造这些化合物的方法以及使用这些化合物的方法，包括治疗与KEAP1-Nrf2相互作用相关的疾病状态、紊乱和病症的方法，例如炎症性肠病，包括克罗恩病和溃疡性结肠炎。
• INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP3833662A2

  公开（公告）日：2021-06-16